Popular Keywords

Amyotrophic Lateral Sclerosis (ALS)

Applied Neurobiology

Brain disease

Cellular Biology

Clinical Neurology

CNS Injury and Stroke

Adenocarcinoma of uncertain primary aetiology in a 40-year-old patient with cavernous sinus thrombosis

Correspondence to Author: Sravan Kumar Reddy Edamakanti, 

Gandhi Medical College,Secunderabad, India


In this article, we present a case of bilateral cavernous sinus thrombosis in a 40-year-old man with nasopharyngeal adenocarcinoma of unidentified primary aetiology. Cave-like Sinus An rapid development of unilateral periorbital edoema, headache, photophobia, and eye bulging are symptoms of thrombosis. Ptosis, chemosis, and cranial nerve palsies are a few additional frequent presenting signs. Anticoagulation was initially used to treat the patient until subsequent testing revealed the widespread metastatic disease. Here, we’ve covered the clinical presentation, exam findings, radiological evidence, and management.

Introduction: A extremely uncommon illness, cavernous sinus thrombosis (CST) has an incidence of 0.2–1.6 cases per 100,000 people annually [1]. Malignancy is the source of 7.4% of all instances of cerebral and dural venous sinus thrombosis, indicating that the risk of CST is five times higher in malignancy [2]. In the days before antibiotics, it was linked to a high mortality rate [3]. The mortality rate is still significant, at 30%, and up to 50% of patients have residual cranial neuropathies even when antibiotics and other contemporary medical care techniques are used [4]. Therefore, accurate diagnosis of the cause of CST is essential for effective care. The primary symptoms of CST were how our patient, who had an advanced occult cancer with extensive metastases, presented. Diagnosis diagnosis of Cavernous Sinus Thrombosis is difficult and requires a thorough grasp of the disease process and a high index of clinical suspicion because these patients don’t always present with the typical symptoms, which makes it more difficult [5]. We present a rare case of left-sided CST that subsequently spread to the right side in a 40-year-old man with widespread adenocarcinoma metastasis of unknown initial origin. Malignancy is a very uncommon cause of CST.

ConclusionThere are extremely few examples described in the literature of CST in the presence of cancer. When considering anticoagulation as a therapy option for individuals with cancer, the risks and benefits should be carefully weighed individually.

References1. Tadi, P., Behgam, B., and Baruffi, S. “Cerebral venous thrombosis”.InStatPearls 2021. 2. Silvis, S.M., et al. “Cancer and risk of cerebral venous thrombosis: a 3. Southwick, F.S,. et al. “Septic thrombosis of the dural venous sinuses.:”Med. 65.2(1986):82-106. 4. Desa, V., and Green, R. “Cavernous sinus thrombosis: current therapy”.J Oral Maxillofac Surg.70.9(2012):2085- 2091. 5. Matthew, T.J., and Hussein, A. “Atypical cavernous sinusthrombosis: a diagnosis challenge and dilemma”. Cureus.10.12(2018). 6. DiNubile, M.J. “Septic thrombosis of the cavernous sinuses”. Arch Neurol.45.5(1988):567-572. 7. https://www.ncbi.nlm.nih.gov/books/NBK459244/ figure/article-19031.image.f2/ 8. Rogers, L.R. “Cerebrovascular complications in patients with cancer”.InSeminars Neurol. 30.3(2010):311-319. 9. Logothetis, C.N ., and Pizanis, C. “Cerebral venous thrombosis in the setting of malignancy: Case reportand review of the literature”. Case Rep Hematol. 2020. 10. Ferro, J.M et al. “Safety and efficacy of dabigatran etexilate vs doseadjusted warfarin in patients with cerebral venous thrombosis: a randomized clinical trial”. JAMA Neurol.76.12(2019):1457-1465. 11. Abelhad, NI., et al. “Thrombosis and bleeding outcomes in the treatment of cerebral venous thrombosis in cancer”. Thromb J.Dec;19.1(2021):1-6.


Sravan Kumar Reddy Edamakanti. Adenocarcinoma of uncertain primary aetiology in a 40-year-old patient with cavernous sinus thrombosis. Clinics of Neurology 2024.

Journal Info

  • Journal Name: Clinics of Neurology
  • Impact Factor: 2.1**
  • ISSN: 2836-256X
  • DOI: 10.52338/Conr
  • Short Name: CONR
  • Acceptance rate: 55%
  • Volume: 6 (2024)
  • Submission to acceptance: 25 days
  • Acceptance to publication: 10 days


  • Crossref indexed journal
  • Publons indexed journal
  • Pubmed-indexed journal
  • International Scientific Indexing (ISI)-indexed journal
  • Eurasian Scientific Journal Index (ESJI) index journal
  • Semantic Scholar indexed journal
  • Cosmos indexed journal


  • International Reach
  • Peer Review
  • Rapid Publication
  • Open Access
  • High Visibility